Pivotal Data For the Treatement of XLRP

Show Description +

Dr. Sisk provides an update on the VISTA trial of laru-zova (Beacon Therapeutics), a subretinal gene therapy for X-linked retinitis pigmentosa. The trial met it's primary endpoint with a significant portion of patients achieving 3 or more lines of low-luminance visual acuity.

Posted: 10/15/2026

Keywords:

VISTA

•

Clinical Trials

•

laru-zova

•

Beacon Therapeutics

•

Subretinal

•

Gene Therapy

•

x-linked

•

Retinitis pigmentosa

•

low-luminance

•

Visual Acuity

•

retina-meeting-recap

•

Retina Subspecialty Day

Up Next

Name: Pivotal Data For the Treatement of XLRP
Uploaded: 2026-10-15T19:23:20+00:00
Description: Dr. Sisk provides an update on the VISTA trial of laru-zova (Beacon Therapeutics), a subretinal gene therapy for X-linked retinitis pigmentosa. The trial met it's primary endpoint with a significant portion of patients achieving 3 or more lines of low-luminance visual acuity.